Content overview: “Artiva Biotherapeutics Halts Autoimmune Cell Therapy Trial After Two Patient Deaths | Nova”. Artiva Biotherapeutics is shutting down its clinical trial of an experimental cell therapy for autoimmune diseases following the deaths of two participants. The San Diego-based company had been testing AlloNK, an off-the-shelf natural killer cell therapy, in patients with lupus nephritis. The trial's stoppage marks a significant setback for the emerging field of applying cancer cell therapy strategies to autoimmune conditions, which has attracted major investment from pharmaceutical companies.
While the specific causes of death were not disclosed, the fatalities raise safety concerns about using potent immune-modulating therapies in patients whose conditions are not immediately life-threatening. The news sent ripples through the biotech sector, as several other companies are pursuing similar approaches for diseases like lupus, rheumatoid arthritis, and multiple sclerosis. Analysts note that the autoimmune cell therapy space may face increased regulatory scrutiny following this incident. The full version stays on the original page, which this listing opens directly.